Free Trial
NASDAQ:GDTC

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

CytoMed Therapeutics logo
$0.77 -0.07 (-8.53%)
As of 11/13/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About CytoMed Therapeutics Stock (NASDAQ:GDTC)

Advanced

Key Stats

Today's Range
$0.78
▼
$0.83
50-Day Range
$0.78
▼
$1.01
52-Week Range
$0.68
▼
$2.29
Volume
9,291 shs
Average Volume
12,479 shs
Market Capitalization
$9.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.16
Consensus Rating
Hold

Company Overview

CytoMed Therapeutics Ltd. is a Singapore-based biotechnology company developing cell-based immunotherapies for cancer. Its research focuses on gamma delta T cells, a type of immune cell, and induced pluripotent stem cell-derived cells for potential use in cancer treatment.

The company is developing allogeneic therapies, which are made using cells from donors rather than each patient’s own cells. Its programs are in development, and CytoMed does not have a marketed cancer treatment.

Founded in 2018, CytoMed conducts research and development in Singapore and has pursued clinical development activities in the region. Its work is focused on advancing potential therapies through development and testing rather than serving patients through a commercial product portfolio.

AI Generated. May Contain Errors.

CytoMed Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

GDTC MarketRank™: 
2.614039700275 of 5 stars

CytoMed Therapeutics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytoMed Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    CytoMed Therapeutics has a consensus price target of $4.16, representing about 401.6% upside from its current price of $0.83.

  • Amount of Analyst Coverage

    CytoMed Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about CytoMed Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    CytoMed Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.15% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 1.81, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 9.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CytoMed Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytoMed Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    CytoMed Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for CytoMed Therapeutics this week, compared to 1 article on an average week.
Receive GDTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GDTC Stock News Headlines

CytoMed Therapeutics (NASDAQ:GDTC) Stock Falls 1% - Here's Why
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Headlines

GDTC Stock Analysis - Frequently Asked Questions

CytoMed Therapeutics' stock was trading at $1.3350 at the start of the year. Since then, GDTC shares have decreased by 37.9% and is now trading at $0.8293.

CytoMed Therapeutics Limited (NASDAQ:GDTC) announced its quarterly earnings results on Wednesday, September, 30th. The company reported $0.05 EPS for the quarter. The firm had revenue of $60.77 thousand for the quarter.

CytoMed Therapeutics (GDTC) raised $11 million in an initial public offering (IPO) on Wednesday, April 12th 2023. The company issued 2,412,369 shares at a price of $4.00-$5.00 per share.

Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
9/30/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GDTC
CIK
1873093
Fax
N/A
Employees
42
Year Founded
2018

Price Target and Rating

High Price Target
$4.16
Low Price Target
$4.16
Potential Upside/Downside
+401.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.07
Current Ratio
2.64
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$250 thousand
Price / Sales
39.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.45 per share
Price / Book
1.84

Miscellaneous

Outstanding Shares
11,830,000
Free Float
N/A
Market Cap
$9.81 million
Optionable
Not Optionable
Beta
0.01

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:GDTC) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners